]MRB is one of the most promising radioligands used to measure brain norepinephrine transporters (NET) with positron emission tomography (PET). The objective of this study was to evaluate the suitability of [ 11 C]MRB for drug occupancy studies of NET using atomoxetine (ATX), a NET uptake inhibitor used in the treatment of depression and attention-deficit hyperactivity disorder (ADHD). A second goal of the study was identification of a suitable reference region. Ten PET studies were performed in three anesthetized rhesus monkeys following an infusion of ATX or placebo. ]MRB plasma free fraction. ATX IC 50 was estimated to be 31 ± 10 ng/mL plasma. This corresponds to an effective dose (ED 50 ) of 0.13 mg/kg, which is much lower than the therapeutic dose of ATX in ADHD (1.0-1.5 mg/kg). [ 11 C]MRB binding potential BP ND in the thalamus was estimated to be 1.8 ± 0.3. Defining a reference region for a NET radiotracer is challenging due to the widespread and relatively uniform distribution of NET in the brain. Three regions were evaluated for use as reference region: caudate, putamen and occipital cortex. Caudate was found to be the most suitable for preclinical drug occupancy studies in rhesus monkeys. The IC 50 estimate obtained using MRTM2 BP ND without arterial blood sampling was 21 ± 3 ng/mL (using caudate as the reference region). This study demonstrated that [ 11 C]MRB is suitable for drug occupancy studies of NET.
Introduction
The brain norepinephrine transporter (NET) is responsible for norepinephrine reuptake, as well as dopamine reuptake in some regions such as the frontal cortex. (Morón et al., 2002) . The ability to quantify the density of these transporters in vivo with positron emission tomography (PET) would provide an important means to study the role of NET in various psychiatric and behavioral disorders in which they are implicated, such as attention deficit hyperactivity disorder (ADHD) (Spencer et al., 2002) , substance abuse and depression (Barker and Blakely, 1995; Ding et al., 2006 , review and references within). However, PET imaging of norepinephrine transporters has long been hampered by the lack of suitable radioligand (Ding et al., , 2006 . Drawbacks of early candidate radiotracers included very low specific binding and the lack of a suitable reference region. The challenges for NET imaging are in part fundamentally due to the widespread distribution of NET in the brain, and the lower contrast in transporter density between NET-poor and NET-rich regions (Smith et al., 2006) than for the other monoamine transporters like DAT (Kaufman et al., 1991) or SERT (Zeng et al., 2006) . Furthermore, the locus coeruleus, the highest NET density region, is difficult to localize and quantify with PET due to its small volume. Currently, the best radioligands available are derivatives of reboxetine: (S,S)-[ (Ding et al., 2003; Schou et al., 2003; Wilson et al., 2003) (Schou et al., 2004) . They have higher specific binding and lower variability in non-specific binding than previous radioligands (Ding et al., 2006) . When [ 11 C]MRB was initially tested in a drug occupancy study in humans using Atomoxetine (ATX), a reduction in [ 11 C]MRB binding was reported, but there was no obvious dose-dependent effect . ATX is a potent norepinephrine transporter reuptake inhibitor (K i~5 nM) currently used in the treatment of depression and ADHD (Spencer et al., 2002) . One hypothesis was that the doses of ATX examined in the human PET study, though clinically relevant, were too high. That is, the three tested doses all reached saturation, the plateau portion of the corresponding dose-occupancy curve, and, as a result, there was no obvious dose-dependent effect. Another occupancy study of ATX using [ 
Materials and methods

Study design
In order to maintain a constant concentration of ATX in the plasma during the PET acquisition time, a continuous infusion protocol was used. This protocol was similar to the one used in the study with [ 18 F]F-MeNER-D 2 (Seneca et al., 2006) . Two infusion rates were used ( Fig. 1 ): 2 h before the beginning of each PET scan, the first ATX infusion at the "loading" rate was begun; then, 1 h before the injection of [ 11 C]MRB and the beginning of the PET scan, the infusion rate was lowered by 37.5% (i.e., "maintenance" rate). This infusion rate (MIR ATX ) was maintained until the end of PET scan. Initially the maintenance rates were 0.01 mg/kg/h (low dose), 0.05 mg/kg/h (medium dose) and 0.012 mg/kg/h (high dose). After analysis of the data from the first two monkeys (6 scans), the medium and high-dose rates were lowered to 0.03 mg/kg/h and 0.09 mg/kg/h, respectively.
The design was to have each monkey have four PET scans on 2 study days. These 2 study days were scheduled 2 weeks apart to allow recovery from the effects of the anesthesia and blood drawing. On each study day, two PET scans were acquired, beginning 4 h apart. The first study day consisted of the baseline and medium-dose scans, the second study day consisted of the low-and high-dose scans.
Study population
Three non-human primates (Rhesus macaque, 5.5 ± 1.4 years old and weighing 6.7 ± 1.4 kg) were scanned. Only two monkeys were scanned four times. The second monkey could not be scanned on the second study day, due to the unavailability of arterial samples. Thus, only baseline and medium-dose scans were acquired for that animal. All study procedures were performed under a protocol approved by the Yale University Institutional Animal Care and Use Committee.
Radiochemistry
Both the MRB standard and precursor were prepared previously (Lin and Ding, 2004 . The total radiosynthesis time was~40 min with an average specific activity of 264 ± 107 MBq/nmol (7± 3 mCi/nmol) at the end of synthesis (n =10). The final formulated product was N98% radiochemically pure. The average injected dose was 247 ± 20 MBq with an average specific radioactivity of 129 ± 46 MBq/nmol at the time of injection. The average injected mass was 0.57 ± 0.23 μg.
PET imaging
Animals were initially anesthetized with an intramuscular injection of ketamine hydrochloride, intubated and transported to the PET facility. They were maintained on oxygen and isoflurane (1.5-3%) throughout the study. Scans were performed with the High Resolution Research Tomograph (HRRT) (Siemens/CTI, Knoxville, TN, USA) PET scanner which acquires 207 simultaneous slices with 1.2 mm inter-slice distance and resolution of~3 mm. Following a 6-min transmission scan, [ 11 C]MRB was injected over 2 min by an infusion pump (Harvard PHD 22/2000, Harvard Apparatus, Holliston, Massachusetts, United States). List-mode data were acquired for 120 min. Dynamic scan data were reconstructed with all corrections (attenuation, normalization, scatter, randoms, and deadtime) using the MOLAR algorithm Johnson et al., 2004) with 2 iterations and 30 subsets. A sequence of 33 frames was reconstructed with the following timing: 6 ×30 s; 3 ×1 min; 2 ×2 min; 22×5 min.
Arterial input function measurement
In order to measure the time-concentration curve of [ 11 C]MRB, 21 blood samples were drawn at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 15, 20, 25, 30, 40, 50, 60, 75, 90, 105, 120 min after the injection of [ 11 C]MRB. Sample volumes were approximately 0.5 mL. Samples drawn at 10-, 20-, 40-, 60-and 90-min postinjection had a volume of 1.5 mL in order to measure the fraction of unchanged [ 11 C]MRB in plasma by HPLC. Plasma was separated from blood cells by centrifugation (3900g for 5 min at 4°C; Allegra X-22R Centrifuge, Beckman Coulter, Fullerton, CA, USA). Whole blood and plasma samples were counted in a cross-calibrated well counter (Wizard 1480, Perkin Elmer, Waltham, MA, USA).
For the metabolite samples, plasma proteins were precipitated using acetonitrile (1 mL/mL plasma) and centrifugation (14,000g for 5 min; Minispin plus centrifuge, Eppendorf, Westbury, NY, USA). The supernatant was counted and 0.2 mL was analyzed by reverse-phase HPLC. The HPLC system consisted of an isocratic pump (LC-20A1, Shimadzu, Kyoto, Japan), an injector (7725i, Rheodyne, Rohnert Park, CA, USA) equipped with a 2 mL sample loop, a Luna C18(2) column (semi-prep, 4.6×250 mm, 10 μm, Phenomenex , Torrance, CA, USA). The column was eluted with a mixture of acetonitrile and aqueous 0.1 M ammonium formate (pH 4.2) in a ratio of 32:68 at a flow rate of~4.2 mL/min. The output of the HPLC column was connected first to an UV detector (SPD-20A, Shimadzu, Kyoto, Japan), then to an inline gamma counter (Flow-Count Radio-HPLC Detector, Bioscan, Washington, DC, USA) and finally to a fraction collector (CF-1 Fraction Collector, Spectrum Chromatography, Houston, TX, USA). Collection tubes were manually Study timelines for the two-day, four-dose studies (Day 1: baseline and mediumdose studies; Day 2: low-and high-dose studies). The solid line represents the ATX infusion rates (i.e., loading rate followed by maintenance rate for each study), as used for monkey #3 (i.e., the maintenance rates were 0.01 mg/kg/h (low dose), 0.03 mg/kg/h (medium dose) and 0.09 mg/kg/h (high dose)). The grey areas highlight the PET scanning times. The black triangles represent the PK sampling times.
shifted based on the detection of the parent compound peak with the inline gamma counter. Fractions were then counted in a well counter. The ratios of the radioactivity concentrations in supernatant and plasma were obtained and fitted to a quadratic curve (f S ). The unchanged (i.e., unmetabolized) fraction of the tracer in the supernatant was fitted to an integrated gamma function:
The unchanged tracer fraction in plasma was then computed as the product of the functions f S and f H . Both functions were extrapolated from 90 min (time of the last sample analyzed by HPLC) to 120 min. MRB was added (b25 μl/mL blood from the dose vial) to a blood sample withdrawn before injection to produce a blood standard. After mixing and centrifugation of red blood cells, plasma filtrate was separated from plasma proteins using ultrafiltration tubes (Centrifree UF device number 4104, Millipore, Billerica, MA, USA) and centrifugation (1100g for 20 min; IEC Medilite centrifuge, Thermo Fisher Scientific, Waltham, MA, USA). Plasma and filtrate samples were counted in triplicate and free fraction (f P ) was estimated as the ratio of the mean concentrations in filtrate and plasma.
ATX plasma levels
In addition to the samples used to determine [ 11 C]MRB radioactive concentration in plasma, four 3-mL blood samples were drawn 60, 120, 180, and 240 min post-ATX infusion (or 60 min before and 0, 60 and 120 min after tracer injection) to determine the ATX concentration in plasma. Red blood cells were precipitated; the plasma was frozen and then shipped for analysis. The plasma level of ATX was quantified with capillary gas chromatography-mass spectrometry (Analytical Psychopharmacology Laboratory, Nathan Kline Institute, Orangeburg, NY). The rate of variation of ATX concentration in plasma during the PET scan was estimated by fitting the 0-, 60-and 120-min sample values (post tracer injection) with a mono-exponential function.
Magnetic resonance imaging
MR images were acquired for each rhesus monkey on a Siemens 3.0T Trio scanner, using an extremity coil. T1-weighted images were acquired in the coronal plane with a spin echo sequence (TE = 3.34, TR = 2530, flip angle = 7°, section thickness = 0.50 mm, field-ofview = 140 mm, image matrix = 256 × 256 × 176 pixels, matrix size = 0.5469 × 0.5469 × 0.5000 mm). Non-brain was removed and cropped to 176 × 176 × 176 pixels using MEDx software (Medical Numerics Inc, Germantown, MD, USA) before co-registration with PET Images.
Regional TAC computation
In order to compute regional time activity curves (TAC), selected regions of interest (ROIs) ). To transfer this template of regions to the PET dynamic images, two transformations were estimated: first, a nonlinear transform between the template MR image and each monkey MR image was computed using the bioimagesuite software (www.bioimagesuite.org); then, a rigid coregistration matrix was estimated between each monkey MR and an early PET sum image from each study (0-10 or 5-10 min postinjection), using a normalized mutual information algorithm (FLIRT, www.fmrib.ox.ac.uk/fsl/flirt/index.html).
Quantification of [
C]MRB distribution volume
Based on previous modeling studies of [ 11 C]MRB kinetics Gallezot et al., 2007) , [ 11 C]MRB volume of distribution (V T ) was estimated using the multilinear analysis MA1 (Ichise et al., 2002) and the following equation:
where the parameter b is equivalent to the y-intercept in the Logan plot (Logan et al., 1990) . When MA1 was applied to the regional time activity curves, t* was set to 30 min. Parametric images of the V T of [ 11 C]MRB were also computed using MA1. In these pixel-by-pixel analyses, t* was set to 10 min.
Quantification of [
C]MRB binding potential without arterial blood sampling
In order to avoid using arterial blood sampling, the ratio of the V T of [ 11 C]MRB in a target region (or voxel) to that in a reference region, V T /V Ref , was estimated using MRTM2 (Ichise et al., 2003) . MRTM2 is based on the multilinear reference tissue model (MRTM) (Ichise et al., 1996 (Ichise et al., , 2003 and the following equation:
where the parameter b' is the y-intercept in the Logan plot of the reference region. The parameter b' is also equal to the value of the parameter b, in Eq. (2), for the reference region. Therefore, in theory, the parameter b' should be identical in all voxels or regions for any given scan. However, in MRTM, one value of b' is estimated per ROI or voxel. With MRTM2, only one value of b' is estimated per scan in order to reduce the variability of the other parameter estimates. MRTM2 is a two-step procedure. In the first step, MRTM was applied to all brain voxels to produce parametric images of BP ND , b and b', as well as a parametric image of the standard error σ b′ of parameter b' determined from the linear fit. Then a global estimate of b' was computed using the following weighted mean formula over all brain voxels:
Then, in the second step, MRTM was reapplied to all brain voxels using the aforementioned b' value as a fixed parameter, to produce improved parametric images of BP ND and b. To compute these MRTM2 parametric images, only the caudate nucleus was used as reference region.
Estimation of ATX IC 50 and ED 50
Three indexes of [ 11 C]MRB binding were compared to highlight the dose-dependent effect of ATX and quantify its IC 50 : the normalized distribution volume V T /f P , and the binding potentials BP F and BP ND (Innis et al., 2007) . V T /f P and BP F values were obtained from the MA1 V T estimates. BP ND values were obtained either from the MA1 V T estimates or directly from the MRTM2 analyses. The effect of ATX on these three indexes was quantified using the following equations:
where C ATX is the average concentration of ATX measured in the plasma during the PET scan (i.e., the average of the three samples taken 120, 180 and 240 min after the beginning of the ATX infusion), B max is the NET density, K d is [ (6) and (7) are 2-parameter equations (B max /K d and the IC 50 for Eq. (6); f ND B max /K d and the IC 50 for Eq. (7)), and are based on the assumption that V ND in the target tissue is equal to V T in the reference region (i.e., V ND =V Ref ). Three candidate reference regions were evaluated: putamen, caudate nucleus and occipital cortex. IC 50 estimates were obtained using each target region by pooling data from all monkeys. For each region, data from all monkeys was pooled, and fitted with one set of parameters, ignoring the effects of the population variability of
Alternatively, the percentage of occupancy was estimated for each scan using the Lassen plot (Lassen et al., 1995; Cunningham et al., 2010) . This method assumes that all the regions included in the analysis have identical non-specific binding (i.e. V ND /f P ) and ATX occupancy level. Therefore, regions which were estimated to have different V ND /f P values were excluded (see results). In the Lassen plot, the reduction of V T /f P between a baseline scan and a post-drug scan is plotted against the corresponding V T /f P estimates at baseline. Then, ATX occupancy was estimated for each scan as the slope of the regression line. Then, ATX IC 50 was estimated by fitting the curve representing ATX occupancy versus the ATX plasma concentration C ATX using the following equation:
Finally, the IC 50 estimates (ng/mL plasma) were converted to ED 50 estimates (mg/kg/h) using the linear correlation between the measured ATX plasma levels and the infusion rates.
Data weights, parameter estimation and statistical analyses
Parameters V T (for MA1) and BP ND (for MRTM2) were estimated using multilinear weighted least squares, with weights based on the noise-equivalent counts in each frame. For the estimation of ATX IC 50 , nonlinear parameter estimation was performed using a MarquardtLevenberg algorithm (Marquardt, 1963) and custom software for IDL 6.2 (ITT Visual Information Solutions, Boulder, CO, USA). Standard errors on the fitted parameters were estimated using the theoretical covariance matrix (Beck and Arnold, 1977, chapter 7.7.1) .
Standard errors on the plasma free fraction (σ f P ) were estimated using the standard deviation of the triplicate measurements of plasma (σ C plasma ) and ultrafiltrate (σ C ultrafiltrate ) samples, and the error propagation equation. Similarly, the standard error on the normalized distribution volumes V T /f P were also computed using the error propagation equation.
F tests were used to determine whether the parameters IC 50 and V ND /f P could be shared across NET-rich regions. Similarly, F tests were used to determine whether the parameter B max /K d could be set to zero in the candidate reference regions, or if the value of V ND /f P estimated from a reference region was compatible with data from the highbinding regions.
Results
ATX plasma levels
For all monkeys and all ATX doses, ATX plasma levels could be considered stable 120 min after the beginning of the first infusion (i.e. throughout the PET scan), and ranged between 12 ng/mL and 132 ng/mL ( Fig. 2A-C) . The percent change per hour of ATX plasma level during the PET scan was −1 ± 6%/h. Moreover, ATX plasma levels and the infusion rate were well correlated (Fig. 2D) . The slope of the regression line was 1.04 kg × h/L (body weight × time/plasma volume) (r 2 = 0.902, n = 7, intercept set to zero).
[
C]MRB input function
The radioactivity concentration in whole blood was always slightly lower than that in plasma. The whole blood to plasma concentration ratio was 0.94 ± 0.13 throughout the scans. The fraction of unmetabolized [ 11 C]MRB in plasma quickly decreased initially and then stabilized (Fig. 3A) : it was 42± 8% and 25 ± 4% at 20 and 90 min post-injection, respectively. Since the last parent fraction measurement was only done at 90 min, the metabolite correction from 90 to 120 min was based on the extrapolation of the fits obtained with Eq.
(1) and shown in Fig. 3A . The relative difference between the distribution volumes estimated using 120 min worth of PET data (with extrapolation of the unchanged fraction curve) versus 90 min was +5 ± 6% in the high binding regions and +3 ± 2% in the NET-poor regions.
[ 11 C]MRB plasma free fraction f P was highly variable from scan to scan, with two main trends (Fig. 3B) . First, there was a moderate increase from the first to the second scan of the day (+17% ± 10%). Also, there was a higher day-to-day variability (−16% and −68% for monkey #1 and #3, respectively). The relative standard errors on the free fraction f P measurement were less than 10% for all studies (5% in average) suggesting that these differences were not due to measurement error. Table 1 . The relative standard errors on V T estimates were less than 9% for all studies and ROIs (3% in average). Although the distribution volumes were variable from day to day, especially for monkey #3, V T values estimated in the candidate reference regions were highly correlated with the plasma free fraction f P (e.g., in the caudate nucleus V T =25.2 f P +0.3, r 2 = 0.920, n = 10). The normalized volumes of distribution values (V T /f P ) decreased in a dosedependent manner with increased ATX doses for all monkeys in all the NET-rich regions (Fig. 5) . This relationship was not clearly detectible when V T values were used without f P normalization.
Estimation of ATX IC 50 in high binding regions
Plots of V T /f P values versus the plasma concentration of ATX are displayed in Fig. 6A to C for three NET-rich regions. Using only the normalized distribution values V T /f P , ATX IC 50 values were estimated in four NET-rich regions, without using a reference region. It is possible to fit the data from these four regions with a global IC 50 value and a global V ND /f P value without significantly increasing the residual sum of squares (F 6,28 =0.17, p=0.98) . The global IC 50 estimate was 32±13 ng/mL (rSE = 39%) and the global V ND /f P estimate was 19 ± 4 mL/cm this global IC 50 estimate and the measured ATX plasma concentration, the percentage of occupancy of NET by ATX achieved in this study was estimated to range from 27% (at 12 ng/mL) to 80% (at 132 ng/mL).
Using the global V ND /f P estimate, BP ND was computed as V T /f P at baseline divided by V ND /f P , minus one, and was estimated to range from 1.4±0.2 in the midbrain to 1.8±0.3 in the thalamus (n=3). These BP ND values being very sensitive to the estimation of V ND /f P , a more conservative approach was also used to estimate a lower bound for BP ND : BP ND was computed was V T /f P at baseline divided by V T /f P at the highest doses of ATX, minus one. That is, a 100% occupancy was assumed at the highest doses of ATX in this second approach. With this method BP ND was estimated to range from 1.0 ±0.04 in the midbrain to 1.2 ±0.5 in the thalamus (n=2, since one monkey did not have a high-dose scan).
Evaluation of candidate reference regions
The relative standard error on the aforementioned IC 50 estimate was large (39%) due to the need to estimate the extra parameter V ND /f P . To try to reduce that uncertainty of the IC 50 estimate, and also to potentially avoid arterial blood sampling, the use of a reference region was investigated. The normalized distribution volume values V T /f P at baseline (n = 3) were very similar for all three candidate reference regions, i.e., 30 ± 2 mL/cm 3 , 30±2 mL/cm 3 and 28 ± 3 mL/cm 3 for putamen, occipital cortex, and caudate nucleus, respectively. These baseline V T /f P values were higher than the V T /f P values after blockade by the highest dose of ATX in NET-rich regions: V T /f P was estimated to be 24 ± 3, 26 ± 3, 23 ± 1 and 24 ± 1 in the anterior cingulate cortex, thalamus, midbrain and brainstem, respectively, after blockade by the highest dose of ATX (n = 2). These baseline V T /f P values were also higher than the previously estimated value of V ND /f P in the four high-binding regions (i.e., 19 ± 4 mL/cm 3 ).
These differences could be due to differences in V ND between the candidate reference regions and the high-binding regions, or due to the presence of specific binding in the candidate reference regions.
To test for the presence of specific binding, the curves of V T /f P values versus the plasma concentration of ATX in the three reference regions were fitted using Eq. (5), with the IC 50 parameter fixed to the global value estimated in high-binding regions (i.e., 32 ng/mL). The data was fitted twice, with or without the assumption that B max /K d can be fixed to zero (Fig. 6D to F) , and the two fits were compared using the F test. In the occipital cortex, assuming that B max /K d is equal to zero produced a significantly worse fit (F 1,8 =8.4, p b 0.02). B max /K d was estimated to be 10± 4 mL/cm 3 and V ND /f P was estimated to be 20 ± 3 mL/cm 3 . Thus, a significant specific binding was detected in occipital cortex; this region was thus excluded from the list of candidate reference regions. In the putamen, assuming that B max /K d is equal to zero did not produce a significantly worse fit (F 1,8 =0.07, p =0.8). V ND /f P was then estimated to be 30± 1 mL/cm 3 . In the caudate, there was a trend-level, but not significant, difference between the two fits (F 1,8 =3.0, p = 0.12). With the two-parameter fit, B max /K d was estimated to be 6 ± 4 mL/cm 3 and V ND /f P was estimated to be 23 ± 2 mL/cm 3 . With the one-parameter fit, V ND /f P was estimated to be 26 ± 1 mL/cm 3 . To test whether the estimate of V ND /f P from the putamen (or caudate) is significantly different from the estimate of V ND /f P from the high-binding regions, the high binding region curves were fitted twice, with or without fixing V ND /f P to the value estimated in the putamen (or caudate), and the two fits were compared using the F test. Using the V ND /f P value estimated in the putamen (i.e., 30 mL/cm 3 ) as a fixed parameter to fit the high- binding region data lead to significantly worse fits (F 1,34 =17.6, pb 0.001). Similarly, using the V ND /f P value estimated in the caudate (i.e., 26 mL/cm 3 ) as a fixed parameter to fit the high-binding region data lead to significantly worse fits (F 1,34 =6.0, pb 0.02). Thus, putamen and caudate are also not perfectly valid reference regions.
Estimation of the bias on IC 50 estimates when using caudate or putamen as the reference region Using the caudate as the reference region and the binding potential BP ND (deduced from MA1 V T estimates), ATX IC 50 was estimated to be 21± 4 ng/mL (rSE =18%), which is 36% lower than the IC 50 estimate obtained without using a reference region. Similarly, ATX IC 50 was estimated to be 19± 3 ng/mL (rSE=16%) when using BP F (bias=−39%). Using the putamen as the reference region and either BP ND or BP F , ATX IC 50 was estimated to be 9±2 ng/mL (rSE=28%), which is 72% lower than the estimate without using a reference region. Thus, the IC 50 estimate was both more biased and less precise when using the putamen rather than the caudate nucleus. Additionally, the IC 50 estimates obtained using caudate-based BP ND or BP F values are not significantly lower than the IC 50 estimate obtained using V T /f P (F 1,34 b 2.3, pN 0.14), but the IC 50 estimates obtained using putamen-based BP ND or BP F values are significantly lower (F 1,34 =12.6, pb 0.002).
In order to avoid arterial blood sampling, [ 11 C]MRB binding potentials were also estimated directly using MRTM2 and the caudate nucleus as a reference region. The estimates of BP ND obtained with MRTM2 and MA1 were highly correlated (y = 0.993 x + 0.021, r 2 =0.949, n = 70, where x and y represent MA1 and MRTM2 regional BP ND estimates, respectively). MRTM2 BP ND parametric images are visually almost identical to MA1 BP ND images, except for a few artifacts in the images from scans following administration of the highest doses of ATX (data not shown). Consequently, the IC 50 estimate obtained using MRTM2 BP ND estimates (21 ± 3 ng/mL) was very similar to the one obtained using MA1 BP ND estimates (21 ± 4 ng/mL).
Improving IC 50 estimates by using occipital as a low binding region
Another approach was tested to reduce the standard error on the IC 50 estimate: fitting the four high binding regions together with the occipital cortex since both V ND /f P and the IC 50 seemed similar in these five regions, using Eq. (5). The relative standard error on V ND /f P and IC 50 estimates could be slightly reduced to 15% and 31% (from 22% and 39%, respectively, without including the occipital in the analysis) with negligible changes in the estimates themselves: V ND /f P and IC 50 estimates are then 19± 3 mL/cm 3 and 31±10 ng/mL (from 19±4 mL/cm 3 and 32±13 ng/mL, respectively). B max /K d was estimated to 11± 4 in the occipital cortex. Estimating ATX IC 50 using the Lassen plot
Lassen plots obtained for the three animals are shown in Fig. 7A -C. The four high binding regions and the occipital were included in the analysis, since the previous analyses showed that V ND /f P and the IC 50 were not significantly different in these regions. ATX occupancy estimates were 31± 10%, 56± 7% and 86± 13% for the low-, medium-and high-dose scans for monkey 1, 65± 18% for monkey 2, and 39±14%, 63± 7% and 82± 6% for the low-, medium-and high-dose scans for monkey 3. The relationship between these ATX occupancy estimates and the measured concentration of ATX in plasma is shown in Fig. 7D . ATX IC 50 was estimated to be 28±7 ng/mL with this method. This IC 50 value is in excellent agreement with the value obtained above using the nonlinear fit.
Discussion
In this study, we demonstrated that [ Finally, the suitability of three putative reference regions was investigated. None of them was found to be an ideal reference region, the caudate being the region introducing the least bias in IC 50 estimates based on BP ND calculations. 
Variability of V T estimates and plasma free fraction f P
The substantial variability in the V T estimates for [ 11 C]MRB from scan to scan in anesthetized baboons was previously reported . Consequently, the normalization of the volumes of distribution estimates by some reference region values was found to be critical, even though no ideal reference region could be identified. In this study, high variations of the V T estimates were also observed. As a result, without correction by f P , no dose-dependent reduction of V T estimates could be consistently observed. However, the V T estimates in NET-poor regions were highly correlated with the estimates of the plasma free fraction f P . This result is consistent with the interpretation that a higher plasma free fraction will lead to higher brain uptake and higher values of V T as well as the non-specific distribution volume V ND , specifically V ND = f P /f ND (Innis et al., 2007; Eq. (19) ). Moreover, the normalized distribution volumes (V T /f P ) decreased in a dose-dependent manner with increased ATX doses in the NET-rich regions, and were almost stable or slightly decreasing in the NET-poor regions. Thus, the normalized volume of distribution V T /f P appears to be a suitable index of [ 11 C]MRB binding for occupancy studies. It is also worth noting that the range of the plasma free fraction f P values observed in this study (8% to 31%), is favorable as it can be accurately measured for each study.
Using the estimate of V ND /f P in NET-rich regions (19 mL/cm . The relationship between the normalized distribution volumes (V T /f P ) and the plasma levels of ATX three NET-rich regions: thalamus (A), brainstem (B) and anterior cingulate cortex (C); and in three candidate reference regions: caudate (D), putamen (E) and occipital cortex (F). Data obtained from monkey 1, 2 and 3 and represented with circles, diamonds and squares, respectively. In subfigures A to C, the solid line represents the fit obtained using Eq. (5) to estimate the ATX IC 50 . The parameters IC 50 and V ND /f P were shared across all NET-rich regions. In subfigures D to F, the two lines represent the fits obtained using Eq. (5), with the IC 50 set to the value estimated in NET-rich regions (32 ng/mL), and B max /K D set to zero (dashed line) or fitted (solid line). According to the F test, B max /K D was significantly different from zero in the occipital only.
theory, BP ND should be equal to f ND B max /K D . Therefore, using in vitro estimates of MRB dissociation constant K d (2.5 nM) (Melloni et al., 1984) and of the density of the norepinephrine transporters in the thalamus of rhesus monkeys (23-72 nM) (Smith et al., 2006) , and the present estimate of f ND , then an expected value of the binding potential BP ND in the thalamus can be computed as 0.46-1.44, in good agreement with the present measured values (1.8 ± 0.3 based on the V ND /f P estimates from the fits with Eq. (5); 1.2 ± 0.5 based on V T /f P estimates from the high-dose scans). The cause of the variations of the plasma free fraction f P across experiments in these anesthetized animals could not be explained. No correlations were found between the estimates of the plasma free fraction f P and physiological recordings (pCO 2 , heart rate, respiration rate, level of isoflurane) measured during the anesthesia (data not shown). Interestingly, this f P variation was not observed in humans (Hannestad et al., 2010) .
Estimation of ATX IC 50 for NET
Based on our PET studies, the preferred method to estimate the IC 50 of ATX with [ 11 C]MRB was to fit the V T /f P values obtained for each scan with Eq. (5), using the four high binding regions and the occipital cortex. Since ATX IC 50 and [ 11 C]MRB V ND /f P were not found to be statistically different across these regions, this method is very similar to the Lassen plot method (Lassen et al. 1995; Cunningham et al., 2010) , which assumes that these two variables have identical values in all regions. Consequently, the estimates were very similar (31 vs. 28 ng/mL plasma). The differences between the method used in this study and the Lassen plot method lies in the nature of the estimators (nonlinear versus linear fit; uncorrelated versus correlated variables used for the xand y-axes), and some hypotheses used when estimating V ND /f P (one V ND /f P value estimated for all scans and monkeys using Eq. (5), versus seven V ND /f P values estimated from the Lassen plots).
The IC 50 of ATX for norepinephrine transporters estimated in this study, i.e. 31 ng/mL plasma or 122 nM (ATX molecular weight=255 g/ mol), is compatible with results from previous in vitro studies. Using similar hypotheses as for a radiotracer, the IC 50 of a drug in vivo can be linked to its in vitro affinity (K d ) and its plasma free fraction (f P ), by the equation IC 50 =K d /f p . ATX in vitro K d was estimated to be 3.4 nM in rats (Wong et al., 1982) and 2-5 nM in humans (Tatsumi et al., 1997; Bymaster et al., 2002) . Plasma free fraction of ATX was estimated to be 11-13% in rats Kielbasa et al., 2009) , 3% in dogs and 1.3% in humans . The IC 50 predicted from these K d and f P values would be between 15 nM and 385 nM (i.e., 4-98 ng/mL). Despite the approximations in these calculated values, especially due to the species differences, the order of magnitude matches with the present IC 50 estimate.
The present IC 50 estimate is also compatible with a previous [
18 F] F-MeNER-D2 study in which ATX IC 50 was estimated to 16 ng/mL (Takano et al., 2009a) . Moreover, the IC 50 estimated using MRTM2 and caudate as a reference region, as in that [ 18 F]F-MeNER-D2 study, is even closer (21 ng/mL).
The present estimate of the IC 50 of ATX, 31 ng/mL plasma, is much lower than the plasma levels which were measured during the previous study of ATX and [ 11 C]MRB in humans : there, the plasma levels of ATX were 116, 206, and 421 ng/mL for the three clinically relevant doses of 25, 50 and 100 mg oral ATX, respectively. Based on the present IC 50 estimate, the lack of an obvious dosedependent effect in that study was indeed due to the fact that those three clinically relevant doses all reached saturation with over 78-93% occupancy; i.e., the plateau portion of the corresponding doseoccupancy curve. This extrapolation assumes comparable free fraction of ATX in humans and non-human primates.
Use of a reference region with [
C]MRB in occupancy studies
Norepinephrine transporters are distributed throughout the brain, with relatively low contrast between transporter-poor and transporterrich regions (locus coeruleus excluded). In rhesus monkeys, the lowest densities measured by autoradiography (Smith et al., 2006) were detected in putamen and caudate: in these two regions, the density of NET is about 5 fmol/mg of wet brain tissue, which represents between 7% and 22% of the densities measured in the various sub-nuclei of the thalamus in the same study. In the present study, no significant level of specific binding was detected in the caudate (p = 0.12) and putamen (p = 0.8). However, the non-displaceable binding appeared higher in the caudate (V ND /f P =26 mL/cm 3 ) and putamen (V ND /f P = 30 mL/cm 3 ) than in the NET-rich region (V ND /f P =19 mL/cm 3 ). This lead to an underestimation of BP ND or BP F values, and subsequently to an underestimation of the IC 50 of ATX (by 36-39% with caudate and 72% with putamen). This non-uniform level of non-specific binding throughout the brain has been reported for [ 11 C]MRB in baboons and humans . This issue is also not specific to [ . It is also worth noting that such small between-region difference in non-specific binding may exist for many PET tracers. However, the effect of such variation is more pronounced, and therefore more easily detectible, for tracers with relatively low BP ND values. An alternative possibility is that the apparent higher non-specific binding in the basal ganglia is in fact due to a small amount of specific binding, but that the variability of the V T /f P estimates was too high, or the number of experiment too low, to detect a statistically significant blockade in these NET-poor regions. Finally, one limitation of the present study is that V ND /f P was estimated based on fits of the occupancy data. Studies at higher occupancy levels than in this study (i.e., N90%) would be useful to confirm these findings.
The occipital cortex was investigated since in one in vitro autoradiography study in humans using [ 18 F]F-MeNER-D 2 , the lowest concentration of NET was found in the occipital cortex (Schou et al., 2005) . However, a significant reduction of [ 11 C]MRB V T /f P after ATX infusion was observed in the present study. Conversely, the level of nonspecific binding in the occipital cortex seems to be similar to the one in the main regions of interest. The difference between this study and the aforementioned in vitro autoradiography study could be due to difference of species, as well as differences in the delineation of the region of interest. In fact, the suitability of the occipital cortex as a reference region in humans for [ 11 C]MRB has been assessed by blocking studies in humans: [ 11 C]MRB average V T in the occipital cortex was reduced by 10% after the administration of 100 mg of ATX , and a reduction of 9 ± 17% for V T and 5 ± 15% for V T /f P was observed after the administration of 40 mg of methylphenidate (n =9; Hannestad et al., 2010) . Therefore, the fraction of displaceable binding in the occipital cortex for [ 11 C]MRB may be higher in rhesus monkeys than in humans.
Since the normalized distribution volume (V T /f P ) can be measured accurately and shown to reduce in a dose-dependent manner, it is not necessary to use a reference region for occupancy studies. However, only relying on V T /f P to quantify [ 11 C]MRB binding in an occupancy study would lead to a potentially larger uncertainty in the estimated IC 50 , since there is one additional parameter to be estimated (i.e., the normalized non-displaceable volume of distribution V ND /f P ). To improve the estimation of this extra parameter, an additional scan using a very high dose of the blocking drug (targeting N90% occupancy) would be required. However, using such a high blocking dose of the drug may not be feasible due to the potential toxicity of the drug. Alternatively, using a "reference" region to avoid estimating V ND /f P could lead to some bias in the estimated IC 50 , when the so called "reference" region contains some specific binding, or when that region's non-specific binding is not representative of other regions of interest. This presents a classical trade-off between maximizing precision (i.e., reducing the standard error of the IC 50 estimate) and accuracy (i.e., reducing the bias in that IC 50 estimate). In this study, the caudate nucleus was the "reference" region, which leads to the least bias (36-39%). This bias is not significant as compared to the "gold standard" IC 50 estimate obtained using only V T /f P values. Moreover, similar results were obtained while using the binding potentials BP F and BP ND . The latter could be estimated without arterial blood sampling by using MRTM2 and provided equivalent results to those obtained with the arterial data, i.e., without introducing further bias.
Interestingly, this issue of selecting a reference region seems to be less troublesome in humans since all three NET-poor regions (caudate, putamen and occipital) were considered as reasonable reference regions based on the results of our occupancy study of methylphenidate (Hannestad et al., 2010) . Thus, using MRTM2 with a reference region to quantify [ 11 C]MRB binding without arterial sampling for occupancy studies is feasible in non-human primates and adequate in humans.
Visualization of the locus coeruleus
The region with the highest density of NET, the locus coeruleus, is very small (~10 mm 3 in humans) (Hoogendijk et al., 1995) , and thus challenging to quantify accurately with PET, even with the HRRT and the MOLAR algorithm. [
11 C]MRB binding in the locus coeruleus might still produce a visible signal in rhesus monkeys, but unambiguously identifying the locus coeruleus is not simple: it is not visible on standard T1-weighted MR images, and there are other NET-rich nuclei in the brainstem where the signal may be higher (due to lower partial volume effect) or whose signal may overlap the locus coeruleus signal (due to limited resolution). Noise in the parametric images may also be an issue. Therefore, we limited our quantification to a more global brainstem region. (Seneca et al., 2006) or 0.7 ± 0.1 (Takano et al., 2009a,b Ding et al., 2010; Arakawa et al., 2008) .
The biggest drawback for [
18 F]MeNER-D 2 is its in vivo defluorination which leads to a high uptake of radioactivity in the skull. Though some regions of interest are away from the skull (thalamus, midbrain and brainstem), some part of the cortex, such as the supplemental motor area , have high concentration of NET and may be potentially useful drug targets. The continuously increasing radioactivity in the skull resulting from in vivo defluorination of [ Conversely, the brain time-activity curves are noisy in the late frames with [ 11 C]MRB, as noted in a previous report (Schou et al., 2003) . However, we found that the relative standard errors on the V T estimates were only 3 ± 2% (max= 9%). Another potential drawback of [ 11 C]MRB is that the results from this study suggest that there is up to~30% specific binding, or a higher non-specific binding, in the NET-poor regions (caudate, putamen and occipital), which makes it difficult to choose an ideal reference region. This issue seems to be less troublesome in humans since occipital cortex was considered as a reasonable reference region (Hannestad et al., 2010) . It is not clear whether an ideal reference region is available for [ 18 F]F-MeNER-D 2 in rhesus monkeys, since a detailed comparison of binding potentials estimated using arterial blood sampling versus using a reference region was not performed in the two published occupancy studies in rhesus monkey (Seneca et al., 2006; Takano et al., 2009a) .
In general, F-18 tracers are considered advantageous due to their longer half-live which usually provides better count levels at the end of the scan, especially for tracers with slow kinetics. However, drug occupancy studies may be executed more efficiently with C-11 tracers. Occupancy studies in humans typically include a measurement of baseline receptor availability and at least two measures of occupancy per subject, measured at appropriate times post-dose. In anesthetized animals, it is common to test a range of doses within the same animal. The short half-life of C-11 permits two of these scans to be performed in the same day on the same subject. This reduces the number of visits needed, and scans on one day also tend to have less variability, allowing the study to be accomplished with a smaller sample size of subjects. Furthermore, when proper quantification with arterial input function is needed in humans, thus, the C-11 design is clearly more practical since it can be accomplished in a 2-day study design, with the use of arterial lines in one arm per day.
Conclusions
This study demonstrates that [ The ED 50 of ATX was estimated to be 0.028 mg/kg/h (or 0.13 mg/kg), which is much lower than the therapeutic dose of ATX in ADHD (1.0-1.5 mg/kg). This explains why no obvious dose-dependent effect could be seen in the previous PET occupancy study of ATX in humans .
